Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Long Beach Clinical Trials LLC

Neither a doctor nor a teaching hospital

Research payments

$2,409,442

651 payments

Through program year 2025, Long Beach Clinical Trials LLC is reported as receiving $2,409,442 in research payments, across 651 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $138,735 18
2024 Research $594,023 39
2023 Research $545,778 503
2022 Research $641,933 17
2021 Research $219,712 47
2020 Research $224,579 17
2019 Research $44,682 10

Breakdown

Who paid Research payments · program years 2019–2025
  1. Moderna TX, Inc. $1,470,952 553 payments
  2. Regeneron Pharmaceuticals, Inc. $416,689 17 payments
  3. Novartis Pharmaceuticals Corporation $203,877 2 payments
  4. Sanofi Pasteur Inc. $97,144 7 payments
  5. Invivyd Inc $77,724 4 payments
  6. Endo Pharmaceuticals Inc. $51,046 14 payments
  7. Boehringer Ingelheim Canada Ltd.Ltee $26,520 33 payments
  8. GlaxoSmithKline, LLC. $25,766 10 payments
  9. Teva Pharmaceuticals USA, Inc. $19,256 7 payments
  10. Pfizer Inc. $12,908 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age $656,763 24 payments
  2. A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age $492,822 32 payments
  3. A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 $416,689 17 payments
  4. A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age $286,882 491 payments
  5. A 5-Year, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Assessing the Efficacy, Safety, and Tolerability of Intra-Articular Regimens of Lna043 Versus Placebo in Patients With Symptomatic Knee Osteoarthritis $203,877 2 payments
  6. Canopy $77,724 4 payments
  7. A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above $65,465 4 payments
  8. A Phase 3B, Open-Label, Long-Term Study to Evaluate the Safety and Temporal Pattern of Response of En3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy $40,421 12 payments
  9. A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age $34,485 6 payments
  10. Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older $29,997 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record